Tews Hauke Christian, Schmelter Franziska, Kandulski Arne, Büchler Christa, Schmid Stephan, Schlosser Sophie, Elger Tanja, Loibl Johanna, Sommersberger Stefanie, Fererberger Tanja, Gunawan Stefan, Kunst Claudia, Gülow Karsten, Bettenworth Dominik, Föh Bandik, Maaß Carlos, Solbach Philipp, Günther Ulrich L, Derer Stefanie, Marquardt Jens U, Sina Christian, Müller Martina
Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany.
Institute of Nutritional Medicine, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Inflamm Bowel Dis. 2024 Dec 5;30(12):2405-2417. doi: 10.1093/ibd/izad298.
Accurate biomarkers for disease activity and progression in patients with inflammatory bowel disease (IBD) are a prerequisite for individual disease characterization and personalized therapy. We show that metabolic profiling of serum from IBD patients is a promising approach to establish biomarkers. The aim of this work was to characterize metabolomic and lipidomic serum profiles of IBD patients in order to identify metabolic fingerprints unique to the disease.
Serum samples were obtained from 55 patients with Crohn's disease (CD), 34 patients with ulcerative colitis (UC), and 40 healthy control (HC) individuals and analyzed using proton nuclear magnetic resonance spectroscopy. Classification of patients and HC individuals was achieved by orthogonal partial least squares discriminant analysis and univariate analysis approaches. Disease activity was assessed using the Gastrointestinal Symptom Rating Scale.
Serum metabolome significantly differed between CD patients, UC patients, and HC individuals. The metabolomic differences of UC and CD patients compared with HC individuals were more pronounced than the differences between UC and CD patients. Differences in serum levels of pyruvic acid, histidine, and the branched-chain amino acids leucine and valine were detected. The size of low-density lipoprotein particles shifted from large to small dense particles in patients with CD. Of note, apolipoprotein A1 and A2 serum levels were decreased in CD and UC patients with higher fecal calprotectin levels. The Gastrointestinal Symptom Rating Scale is negatively associated with the concentration of apolipoprotein A2.
Metabolomic assessment of serum samples facilitated the differentiation of IBD patients and HC individuals. These differences were constituted by changes in amino acid and lipoprotein levels. Furthermore, disease activity in IBD patients was associated with decreased levels of the atheroprotective apolipoproteins A1 and A2.
炎症性肠病（IBD）患者疾病活动和进展的准确生物标志物是个体疾病特征描述和个性化治疗的先决条件。我们表明，对IBD患者血清进行代谢谱分析是建立生物标志物的一种有前景的方法。这项工作的目的是表征IBD患者的代谢组学和脂质组学血清谱，以识别该疾病独特的代谢指纹。
从55例克罗恩病（CD）患者、34例溃疡性结肠炎（UC）患者和40名健康对照（HC）个体中获取血清样本，并使用质子核磁共振波谱进行分析。通过正交偏最小二乘判别分析和单变量分析方法对患者和HC个体进行分类。使用胃肠道症状评分量表评估疾病活动度。
CD患者、UC患者和HC个体之间的血清代谢组有显著差异。与HC个体相比，UC和CD患者的代谢组学差异比UC和CD患者之间的差异更明显。检测到丙酮酸、组氨酸以及支链氨基酸亮氨酸和缬氨酸的血清水平存在差异。CD患者中低密度脂蛋白颗粒的大小从大的致密颗粒转变为小的致密颗粒。值得注意的是，粪便钙卫蛋白水平较高的CD和UC患者血清中载脂蛋白A1和A2水平降低。胃肠道症状评分量表与载脂蛋白A2浓度呈负相关。
血清样本的代谢组学评估有助于区分IBD患者和HC个体。这些差异由氨基酸和脂蛋白水平的变化构成。此外，IBD患者的疾病活动与具有抗动脉粥样硬化作用的载脂蛋白A1和A2水平降低有关。
Zotero 插件
